Genentech has announced that the US Food and Drug Administration (FDA) has granted Priority Review (PR) to a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab) for the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD).

The filing acceptance is based on positive results from the phase 3 METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD. This marks the second FDA PR for Enspryng, following the one granted for Thyroid Eye Disease (TED) in June. The FDA is expected to make a decision on approval in MOGAD by January 10, 2027.

Additionally, the European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe. The decision by the European Commission (EC) is expected in the third quarter of 2027.

Levi Garraway, MD, PhD, CMO and Head—Global Product Development, said, “MOGAD can be unpredictable and debilitating, with each relapse carrying the potential for lasting neurological damage, yet there are currently no approved treatments. Enspryng has the potential to transform care for people living with MOGAD, significantly reducing serious attacks and decreasing the reliance on high-dose steroids and immunosuppressants."

The METEOROID study, presented at the American Academy of Neurology (AAN) Annual Meeting in April 2026, met its primary endpoint of time from randomisation to the first MOGAD relapse during the double-blind treatment period.

Enspryng significantly reduced the risk of a new relapse by 68 percent compared to placebo (p=0.0025), with 87 percent of Enspryng-treated patients remaining relapse-free at 48 weeks compared to 67 percent in the placebo arm. Enspryng also provided significant improvements across key secondary measures, including annualised relapse rate, MRI lesion activity and rescue therapy use.

The safety profile in the METEOROID study was consistent with data from more than a decade of Enspryng clinical trial and post-approval experience in neuromyelitis optica spectrum disorder (NMOSD).